Fabrication of Celecoxib PVP Microparticles Stabilized by Gelucire 48/16 via Electrospraying for Enhanced Anti-Inflammatory Action
Pharmaceuticals · 08.02.2023 · 16 (2) · 258
DOI: 10.3390/ph16020258 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 08.02.2023. Verfasst von Samar Zuhair Alshawwa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University.
Abstract (Originalsprache)
Electrospraying (ES) technology is considered an efficient micro/nanoparticle fabrication technique with controlled dimensions and diverse morphology. Gelurice® 48/16 (GLR) has been employed to stabilize the aqueous dispersion of Celecoxib (CXB) for enhancing its solubility and oral bioavailability. Our formula is composed of CXB loaded in polyvinylpyllodine (PVP) stabilized with GLR to formulate microparticles (MPs) (CXB-GLR-PVP MPs). CXB-GLR-PVP MPs display excellent in vitro properties regarding particle size (548 ± 10.23 nm), zeta potential (−20.21 ± 2.45 mV), and drug loading (DL, 1.98 ± 0.059 mg per 10 mg MPs). CXB-GLR-PVP MPs showed a significant (p < 0.05) higher % cumulative release after ten minutes (50.31 ± 4.36) compared to free CXB (10.63 ± 2.89). CXB exhibited good dispersibility, proved by X-ray diffractometry (XRD), adequate compatibility of all components, confirmed by Fourier-Transform Infrared Spectroscopy (FTIR), and spherical geometry as revealed in scanning electron microscopy (SEM). Concerning our anti-inflammatory study, there was a significant decrease in the scores of the inflammatory markers’ immunostaining in the CXB-GLR-PVP MPs treated group. Also, the amounts of the oxidative stress biomarkers, as well as mRNA expression of interleukins (IL-1β and IL-6), considerably declined (p < 0.05) in CXB-GLR-PVP MPs treated group alongside an enhancement in the histological features was revealed. CXB-GLR-PVP MPs is an up-and-coming delivery system that could be elucidated in future clinical investigations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.
- Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.
- Al-Taqaddom Pharmaceutical Industries, Amman 11947, Jordan.
- Pharmaceutical Technology Department, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.
ORCID-Profile: Samar Zuhair Alshawwa, Engy Elekhnawy, Hadil Faris Alotaibi, Al-Sayed Sallam, Dalia H Abdelkader
Förderung
- Princess Nourah bint Abdulrahman University
Zitieren
APA
Alshawwa, S. Z., El-Masry, T. A., Elekhnawy, E., Alotaibi, H. F., Sallam, A. S., & Abdelkader, D. H. (2023). Fabrication of Celecoxib PVP Microparticles Stabilized by Gelucire 48/16 via Electrospraying for Enhanced Anti-Inflammatory Action. Pharmaceuticals, 16(2), 258. https://doi.org/10.3390/ph16020258
Vancouver
Alshawwa SZ, El-Masry TA, Elekhnawy E, Alotaibi HF, Sallam AS, Abdelkader DH. Fabrication of Celecoxib PVP Microparticles Stabilized by Gelucire 48/16 via Electrospraying for Enhanced Anti-Inflammatory Action. Pharmaceuticals. 2023;16(2):258. doi:10.3390/ph16020258
BibTeX
@article{Alshawwa2023,
author = {Alshawwa, Samar Zuhair and El-Masry, Thanaa A and Elekhnawy, Engy and Alotaibi, Hadil Faris and Sallam, Al-Sayed and Abdelkader, Dalia H},
title = {Fabrication of Celecoxib PVP Microparticles Stabilized by Gelucire 48/16 via Electrospraying for Enhanced Anti-Inflammatory Action},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {2},
pages = {258},
doi = {10.3390/ph16020258}
}
EUVIMED